Renalytix PLC
LSE:RENX
Net Margin
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
Peer Comparison
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| UK |
|
Renalytix PLC
LSE:RENX
|
24.5m GBP |
Loading...
|
|
| US |
C
|
Cerner Corp
LSE:0R00
|
31.3B USD |
Loading...
|
|
| US |
|
Veeva Systems Inc
NYSE:VEEV
|
30.2B USD |
Loading...
|
|
| AU |
|
Pro Medicus Ltd
ASX:PME
|
16.5B AUD |
Loading...
|
|
| JP |
|
M3 Inc
TSE:2413
|
1.2T JPY |
Loading...
|
|
| US |
|
Doximity Inc
NYSE:DOCS
|
5.2B USD |
Loading...
|
|
| SE |
|
Sectra AB
STO:SECT B
|
40.1B SEK |
Loading...
|
|
| US |
W
|
Waystar Holding Corp
NASDAQ:WAY
|
4.2B USD |
Loading...
|
|
| CN |
|
Winning Health Technology Group Co Ltd
SZSE:300253
|
24.5B CNY |
Loading...
|
|
| IN |
I
|
Inventurus Knowledge Solutions Ltd
NSE:IKS
|
288.2B INR |
Loading...
|
|
| US |
V
|
Vocera Communications Inc
F:V00
|
2.4B EUR |
Loading...
|
Market Distribution
| Min | -188 120% |
| 30th Percentile | 0% |
| Median | 0% |
| 70th Percentile | 0.1% |
| Max | 10 443.9% |
Other Profitability Ratios
Renalytix PLC
Glance View
Renalytix Plc manufactures medical devices and equipment. The company is headquartered in Penarth, South Glamorgan. The company went IPO on 2018-11-06. The firm is focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care. The firm's diagnostic platform, KidneyIntelX, is designed to scale across kidney disease conditions beyond diabetic kidney disease. The firm is evaluating a range of new indications in chronic kidney disease, cardio-renal disease, chronic kidney disease in diverse populations and coronavirus disease (COVID)-related kidney disease. KidneyIntelX platform facilitates the identification and promotes the effective management of patients at risk of early-stage diabetic kidney disease (DKD), progression by combining diverse data inputs, including validated blood-based biomarkers, inherited genetics, and personalized patient data from electronic health record (HER) using a proprietary algorithm to generate a unique patient risk score.
See Also
Net Margin is calculated by dividing the Net Income by the Revenue.
The current Net Margin for Renalytix PLC is -680%, which is above its 3-year median of -1 455.2%.
Over the last 3 years, Renalytix PLC’s Net Margin has increased from -1 910.2% to -680%. During this period, it reached a low of -1 986.5% on Jun 30, 2024 and a high of -680% on Jul 30, 2025.
